Medtronic plc (MDT) earnings on June 3, 2026
Prior outlook: Pessimistic
Volatly's outlook before the earnings on June 3, 2026: Pessimistic.
MDT price around the earnings
77.95
Change: +4.1%
2026-06-03, 20:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Pessimistic
- Thesis published
Analysts point to an optimistic scenario, but risks remain.
Analysts point to an optimistic scenario due to recent company purchases, but recent price drops and mixed past performance raise concerns about execution.
Context analyzed before publication
- Summary
- Analysts point to an optimistic scenario, but risks remain.
- Playbook
- The scenario suggests clearer signs of positive price movement before investing. Analyst sentiment and company acquisition performance are key factors.
- Trend
- Stock price fell despite analyst optimism.
Analysts
Drivers
-
Analysts
Negative
Some major analysts have recently lowered their ratings to neutral, suggesting growing caution.
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.93
- Analysts covering the stock
- 25
- Average price target
- 106.56
- Lowest price target
- 84
- Highest price target
- 121
- Upside to price target
- 44.5%
- Quarterly earnings growth
- -11.7%
- Revenue growth
- 8.7%
- Forward EPS
- 6.06
- Trailing EPS
- 3.58
- Analyst moves in the last 60 days
- 7
- Strong buy: 2
- Buy: 15
- Hold: 13
- Sell: 0
- Strong sell: 0
- Strong buy
- 2
- Buy
- 15
- Hold
- 13
- Sell
- 0
- Strong sell
- 0
- April 22, 2026 · UBS: Maintains rating (Neutral → Neutral)
- April 15, 2026 · Truist Securities: Maintains rating (Hold → Hold)
- April 13, 2026 · Mizuho: Maintains rating (Outperform → Outperform)
- April 9, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- April 7, 2026 · Citigroup: Maintains rating (Buy → Buy)
- April 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- April 6, 2026 · Argus Research: Maintains rating (Buy → Buy)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (4)
- Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call — Benzinga
- Medtronic To Acquire Maker Of Peripheral Nerve Stimulation Therapies SPR Therapeutics For $650M In Cash — Benzinga
- Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2 — Benzinga
- Orchestra BioMed Receives $20M Investment From Medtronic Under Previously Announced Strategic Financing Agreement — Benzinga
Technicals
Drivers
-
Technical
Negative
The stock's price trend is currently weak, showing significant declines over the past month.
Evidence
- Average true range (ATR)
- 2.1%
- Distance to 52-week high
- -30.6%
- 14-day change (14d)
- -4.0%
- 30-day change (30d)
- -13.3%
- 30-day relative strength
- -13.3%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 73.7
- Nearest resistance
- 74.31
- Volume accumulation ratio (14d / 46d)
- 1.38
Trends
Evidence
- Average earnings surprise
- -6.4%
- February 17, 2026: actual EPS 1.36 vs estimate 1.34 (surprise +1.9%)
- November 18, 2025: actual EPS 1.36 vs estimate 1.31 (surprise +3.5%)
- August 19, 2025: actual EPS 1.26 vs estimate 1.23 (surprise +2.5%)
- May 21, 2025: actual EPS 0.82 vs estimate 1.23 (surprise -33.5%)
Expected move
Drivers
-
Past earnings
Neutral
While the company has often met or exceeded earnings expectations, there have been notable misses in the past.
There is no implied-move data available for this event.
Reactions over its last 19 earnings
- Median move
- 3.1%
- 75th percentile move
- 4.6%
- 90th percentile move
- 5.4%
- Up / down moves
- 8 / 11
- Average up move
- +2.7%
- Average down move
- -4.2%
Monitoring and close
What Medtronic plc reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.